These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9306555)

  • 1. The effectiveness of active specific immunotherapy using interferon-gamma-gene-transduced tumor cells in a murine tumor model.
    Moriguchi Y; Kan N; Okino T; Teramura Y; Yamasaki S; Ichinose Y; Li L; Sugie T; Kuribayashi K; Watanabe Y; Imamura M
    Surg Today; 1997; 27(6):571-3. PubMed ID: 9306555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The induction of specific antitumor immunity by in vivo treatment with interleukin-1 and sonicated tumor extract in a murine model.
    Harada T; Kan N; Okino T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Ohgaki K; Imamura M
    Surg Today; 1994; 24(6):561-3. PubMed ID: 7919743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system.
    Moriguchi Y; Kan N; Okino T; Harada T; Yamasaki S; Ichinose Y; Li L; Sugie T; Imamura M
    J Surg Oncol; 1996 Jun; 62(2):78-85. PubMed ID: 8649045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
    Gorelik L; Mokyr MB
    Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma-producing tumor induces host tumor-specific T cell responses.
    Teramura Y; Watanabe Y; Kan N; Masuda T; Kuribayashi K
    Jpn J Cancer Res; 1993 Jun; 84(6):689-96. PubMed ID: 8340258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide.
    Li L; Okino T; Kan N; Yamasaki S; Ichinose Y; Sugie T; Kanaoka S; Imamura M
    Biotherapy; 1998; 11(4):223-8. PubMed ID: 9950097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential immunotherapy using interleukin-1 followed by interleukin-2 of ascitic MOPC104E-bearing mice.
    Harada T; Kan N; Okino T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Ohgaki K; Imamura M
    Biotherapy; 1993-1994; 7(2):91-9. PubMed ID: 7803195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant effect of a Flt3 ligand (FL) gene-transduced xenogeneic cell line in a murine colon cancer model.
    Kim EM; Sivanandham M; Stavropoulos CI; Wallack MK
    J Surg Res; 2002 Nov; 108(1):148-56. PubMed ID: 12443727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor effects of bone marrow transplantation in combination with fibroblast-mediated IL-2 and IL-3 gene therapy.
    Cao X; Li Q; Ju DW; Wang Q; Tao Q; Wang J
    Transplantation; 1999 May; 67(9):1242-50. PubMed ID: 10342316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
    Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
    Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
    Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
    Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The induction of murine tumor infiltrating lymphocytes (TIL) by interleukin-2 or T cell growth factor.
    Kan N; Mise K; Nakanishi M; Okino T; Harada T; Ichinose Y; Moriguchi Y; Sugie T; Li L; Imamura M
    Biotherapy; 1993; 6(4):303-9. PubMed ID: 8018450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.
    Pajtasz-Piasecka E; Rossowska J; Szyda A; Krawczenko A; Dus D
    Oncol Rep; 2007 May; 17(5):1249-57. PubMed ID: 17390073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
    Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
    Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
    Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P
    Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of a tumor cell vaccine transfected with GM-CSF/IL-2 fusion gene for specific immunotherapy of hepatocellular carcinoma].
    Guo C; Liu QG; Yang W; Yao YM
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):188-92. PubMed ID: 18250039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma.
    Jonak ZL; Trulli S; Maier C; McCabe FL; Kirkpatrick R; Johanson K; Ho YS; Elefante L; Chen YJ; Herzyk D; Lotze MT; Johnson RK
    J Immunother; 2002; 25 Suppl 1():S20-7. PubMed ID: 12048347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.